The blood level of the glial fibrillary acidic protein (GFAP) cellular component increases when astrocytes are damaged or activated. Elevated levels of GFAP in the blood can indicate both the current and future progression of multiple sclerosis.
Injecting the brain molecule into mouse models of multiple sclerosis increased the number of oligodendrocytes. The findings suggest fractalkine may help to slow the progression, or potentially halt multiple sclerosis.
Researchers found significant functional connectivity between multiple sclerosis lesion location and the patient's a priori depression circuit. Findings provide a novel localization of multiple sclerosis-related depression.
Researchers found significantly higher levels of Lcn-2 levels in the stools of patients with multiple sclerosis. This marker correlated with reduced bacterial diversity and increases in other markers of intestinal inflammation. Bacteria that ease inflammatory bowel disease were also reduced in MS patients with high fecal levels of Lcn-2 levels.
Fatigue is a common symptom associated with multiple sclerosis, affecting up to 99% of patients. Researchers report light box therapy helped measurably improve symptoms of fatigue in those with MS after 14 days.